Oliver Engert Buys 1,000 Shares of Enovis (NYSE:ENOV) Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert acquired 1,000 shares of the stock in a transaction dated Friday, March 13th. The stock was acquired at an average cost of $23.74 per share, for a total transaction of $23,740.00. Following the purchase, the insider directly owned 48,640 shares in the company, valued at approximately $1,154,713.60. The trade was a 2.10% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Oliver Engert also recently made the following trade(s):

• On Monday, March 9th, Oliver Engert bought 1,000 shares of Enovis stock. The shares were acquired at an average cost of $23.39 per share, with a total value of $23,390.00.
• On Friday, March 6th, Oliver Engert bought 750 shares of Enovis stock. The shares were acquired at an average price of $24.41 per share, with a total value of $18,307.50.
• On Wednesday, March 4th, Oliver Engert purchased 250 shares of Enovis stock. The stock was acquired at an average price of $25.10 per share, for a total transaction of $6,275.00.
• On Tuesday, March 3rd, Oliver Engert purchased 1,000 shares of Enovis stock. The stock was bought at an average cost of $24.77 per share, for a total transaction of $24,770.00.
• On Friday, February 27th, Oliver Engert acquired 1,000 shares of Enovis stock. The shares were bought at an average price of $25.50 per share, with a total value of $25,500.00.

Enovis Price Performance

Shares of ENOV traded up $0.24 during trading hours on Monday, hitting $23.23. 988,513 shares of the company were exchanged, compared to its average volume of 1,145,921. The company has a debt-to-equity ratio of 0.85, a current ratio of 2.02 and a quick ratio of 1.04. The company has a market capitalization of $1.33 billion, a PE ratio of -1.12 and a beta of 1.46. The firm has a fifty day simple moving average of $23.73 and a 200-day simple moving average of $27.72. Enovis Corporation has a one year low of $21.00 and a one year high of $40.69.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.81 by $0.14. Enovis had a positive return on equity of 8.74% and a negative net margin of 52.69%.The company had revenue of $575.76 million for the quarter, compared to analyst estimates of $584.30 million. During the same period in the previous year, the firm earned $0.98 earnings per share. Enovis’s revenue for the quarter was up 2.6% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, sell-side analysts predict that Enovis Corporation will post 2.79 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ENOV. AQR Capital Management LLC lifted its stake in shares of Enovis by 12.5% in the 1st quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock valued at $2,363,000 after purchasing an additional 7,072 shares during the last quarter. Goldman Sachs Group Inc. increased its position in Enovis by 37.6% during the first quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock worth $10,226,000 after buying an additional 73,116 shares during the last quarter. Empowered Funds LLC increased its position in Enovis by 13.0% during the first quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after buying an additional 749 shares during the last quarter. ProShare Advisors LLC bought a new position in Enovis during the second quarter valued at about $400,000. Finally, Vise Technologies Inc. acquired a new stake in shares of Enovis in the second quarter worth about $208,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on ENOV shares. UBS Group reiterated a “buy” rating and issued a $50.00 target price on shares of Enovis in a report on Monday, January 5th. Canaccord Genuity Group reduced their price target on shares of Enovis from $58.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, December 17th. BTIG Research raised their price objective on shares of Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Needham & Company LLC lifted their price objective on shares of Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Finally, Zacks Research upgraded Enovis from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Enovis presently has an average rating of “Moderate Buy” and an average price target of $47.43.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.